Introducing the Second Analytical Tool to Analyze the Future Competitive Situation of Breast Cancer Therapeutics.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c23843) has announced the addition of Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005 to their offering This is the second analytical tool to analyze the future competitive situation of breast cancer therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development. As new data is emerging, for the recent approved aromatase inhibitor aromatase inhibitor n. A drug that inhibits tumor growth, especially breast cancer, by inhibiting the enzyme aromatase and thereby lowering estrogen levels in the blood or in tumor tissues. , the therapeutic options are about to change. Replacing Tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. , a selective estrogen receptor modulator se·lec·tive estrogen receptor modulator n. Abbr. SERM A nonsteroidal compound, such as raloxifene or tamoxifen, designed to mimic the effect of estrogen on a specific tissue or body part by binding only to that part's estrogen receptors. that has been used for more than 20 years to treat patients with advanced breast cancer. Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval. A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales for the top three breast cancer hormone therapies Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy on the market reaching more than $1.8 billion. "Analytical Tool: Breast Cancer R&D: A Comprehensive Guide" is the ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Those who are victorious in the field plan effectively and change decisively. It provides a complete and systematic description and analysis of the past, present and future efforts in cancer R&D from both industry as well as academic. We have identified structured and defined information necessary to analyze the most candidates currently under development. Our included CD-ROM CD-ROM: see compact disc. CD-ROM in full compact disc read-only memory Type of computer storage medium that is read optically (e.g., by a laser). database contains thousands of records on the issue of R&D and collaborations derived from a multitude of sources, e.g. news releases, company sources, conferences, scientific publications, patents and published interviews etc. This highly updated database reflects the most recent advances in the field. Enabling you to perform your own specific analysis, go back to the source data for in-depth information and to offer you an opportunity to easily produce tables and graphs of the information suited for your own specific purposes. Reasons to purchase this Analytical Tool: - This is the only product that provides you with a complete structure of the areas involved in analyzing breast therapeutics. - It identifies and structures most B2B (Business to Business) Refers to one business communicating with or selling to another. See B2B e-commerce, B2C and B2G. B2B - business to business collaborations and industry-academic alliances - It covers close to all areas of cancer therapeutic strategies, you will be able to study areas in conjunction to cancer structured by therapy type, drug effects, mechanisms/targets and combinatory therapies - It enables you to track cutting edge competitive companies, therapies and technologies in the future market - You will save time and money by rapid identification and analysis of competitors and business opportunities. - You will be able to evaluate progress in both established as well as novel treatment strategies competing within the field of cancer drug development in big pharma. This Analytical Tool includes three parts: Breast Cancer: The Latest R&D Trends Basic Platform Report: Breast Cancer Business Development and R&D Database: Breast Cancer Example of candidates include: The complete number of candidate drugs in clinical research for breast cancer, are more than 150, and some of them below are listed below: Abraxane, Alimta, Arimidex, Aromasin, Avastin, BMS-217380-01, BMS-247550, CAELYX, CCI-779, Faslodex, Femara, Fenretinide, Gleevec, GTI-2040, Herceptin, Iressa, ISIS-2503, Lapatinib, Nolvadex, Sarasar, SDX-105, Tarceva, Theratope Velcade, Zarnestra, Zoladex ZD0473 and many other that are in an earlier stage of development. Companies Mentioned: American Bioscience AnorMED AstraZeneca Biomira Inc Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. Genentech GlaxoSmithKline ISIS Pharmaceuticals Johnson and Johnson Lorus Therapeutics McNeil Pharmaceuticals Merck KgaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. Millennium Pharmaceuticals Millennium Pharmaceuticals NASDAQ: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. Founded in 1993, the company conducts research in various scientific areas, currently focusing on inflammation and oncology. NeoRx Novartis OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ Pfizer Roche Salmedix, Schering-Plough Wyeth For more information visit http://www.researchandmarkets.com/reports/c23843 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion